Conspiracy Theory Posited Over Shire’s Withdrawal Of BLA For Fabry Disease Drug
This article was originally published in The Pink Sheet Daily
Knowledge Ecology International suggests Shire pulled its Replagal BLA in return for rights to Mount Sinai School of Medicine patent that could have blocked sales in Europe; asks FTC to investigate “possible conspiracy” between school, Shire and Sanofi.
You may also be interested in...
Distributed free of charge to U.S. patients with Genzyme’s Fabrazyme in short supply, Replagal seemed destined for quick approval, but FDA has signalled otherwise.
Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.